GlassScriptPhysician profile
Edward B Blackmon
NPI 1114092251
$9,712.16
in general payments reported to CMS, 2019-2025
25 companies · $8,298 in 2025
The $8,298 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $298 · 2022: $453 · 2023: $259 · 2024: $282 · 2025: $8,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Food and Beverage: $1,099 · Travel and Lodging: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Food and Beverage | $1,099.11 |
| Travel and Lodging | $240.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,842.62 | 2025 | |
| Abbvie INC. | $347.07 | 2020-2022 | |
| Exeltis, USA INC. | $327.04 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $173.47 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $148.53 | 2023-2025 | Gemtesa, Myfembree |
| Smith+Nephew, INC. | $137.45 | 2022-2025 | Grafix Pl, Stravix Pl |
| Biogen, INC. | $117.75 | 2024-2025 | Zurzuvae |
| Cumberland Pharmaceuticals, INC. | $81.20 | 2021-2025 | Kristalose |
| Organon LLC | $78.37 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $55.81 | 2022-2023 | Accrufer |
| Krystal Biotech INC | $52.51 | 2025 | Vyjuvek |
| Hologic Sales and Service, LLC | $51.04 | 2024 | Aptima |
| Evofem Biosciences, INC. | $41.48 | 2022 | |
| Therapeuticsmd, INC. | $28.62 | 2022 | |
| Aspira Women'S Health INC | $27.31 | 2024 | Ova1 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $26.62 | 2022-2023 | Balcoltra |
| Lsi Solutions INC | $25.03 | 2020 | |
| Novo Nordisk INC | $24.34 | 2025 | Wegovy |
| Coloplast Corp | $23.95 | 2020 | |
| Myovant Sciences INC. | $22.41 | 2022 | |
| Dexcom, INC. | $21.83 | 2025 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $14.87 | 2021 | |
| Coopersurgical, INC. | $14.74 | 2021 | |
| Astellas Pharma US INC | $14.11 | 2023 | Veozah |
| Mission Pharmacal Company | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Blackmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.